Full-Time

Precision Medicine Director

Posted on 1/27/2025

Tempus

Tempus

1,001-5,000 employees

AI-driven healthcare data analysis platform

Compensation Overview

$150k - $200kAnnually

+ Incentive Compensation + Restricted Stock Units

Senior

Company Historically Provides H1B Sponsorship

Remote in USA

Candidates must be based in MI, OH, IN, or Western PA for remote work.

Category
Healthcare Administration & Support
Medical, Clinical & Veterinary
Required Skills
Excel/Numbers/Sheets
PowerPoint/Keynote/Slides
Requirements
  • Deep understanding of the diagnostic services industry, with strong expertise in molecular diagnostics, genomics, biotechnology, and oncology.
  • Proven ability to engage in consultative selling, overcoming objections while aligning client needs with Tempus’s offerings.
  • Ability to build and leverage cross-functional relationships to achieve work goals and objectives.
  • Capacity to develop innovative solutions using Tempus’s sequencing technology to meet the needs of prospective customers.
  • Strong ability to prioritize tasks, manage multiple projects, and meet critical deadlines while working independently and maintaining proactive communication.
  • Exceptional written and oral communication skills, including proficiency in Microsoft Office tools (Excel, PowerPoint) and effective use of Salesforce.com for tracking and reporting sales activities.
  • Ability to handle sensitive information with a high level of confidentiality and integrity.
  • Ability to travel ~50% within the assigned territory as required.
Responsibilities
  • Identify and prioritize near-term and long-term national and regional strategic accounts that would benefit from Tempus's precision medicine solutions, with a strong focus on oncology, molecular diagnostics, and genomics.
  • Provide business solutions and demonstrate the value of Tempus’s offerings to hospital and laboratory professionals, focusing on the integration of genomic data into clinical workflows.
  • Lead and coordinate the contracting process, including proposal development, to ensure successful partnership agreements with strategic accounts.
  • Collaborate with cross-functional teams, including sales, product, marketing, and customer support, to ensure successful attainment of company goals and objectives for your assigned accounts.
  • Continually analyze the competitive landscape within your assigned accounts, gather customer feedback, and provide insights to Tempus leadership to inform strategy and product development.
  • Stay informed on trends in precision medicine, molecular diagnostics, and genomics, particularly in oncology, and share relevant insights with both internal teams and customers.
  • Embrace and embody Tempus’s company culture at all times, representing the company to both external and internal stakeholders with professionalism and integrity.
Desired Qualifications
  • A Bachelor's degree in a Science or Business-related discipline is required. An advanced degree (MBA, MS, PhD, or healthcare certification) is highly preferred.
  • A minimum of 6+ years of experience in strategic account management or sales within the diagnostic industry, particularly in molecular diagnostics, genomics, or oncology.

Tempus focuses on enhancing patient outcomes through the use of data and artificial intelligence in the healthcare sector. The company offers a platform that analyzes medical data, helping physicians make better treatment decisions by providing insights from medical images and identifying care gaps. For pharmaceutical and biotech companies, Tempus aids in drug development by discovering new targets and assessing treatment effectiveness. Patients benefit from personalized therapy options identified through the platform. Additionally, Tempus conducts research, particularly in cancer, and has developed tools like a pan-cancer organoid platform and a liquid biopsy assay for profiling tumor DNA. The company generates revenue by charging healthcare providers and companies for access to its platform and insights.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Chicago, Illinois

Founded

2015

Simplify Jobs

Simplify's Take

What believers are saying

  • Tempus secured $560 million in debt financing to support growth and acquisitions.
  • Partnerships with Stemline and Artera expand Tempus' AI platform applications.
  • The launch of the Olivia app empowers patients with AI-driven health management.

What critics are saying

  • High debt levels may strain Tempus' financial stability if revenue targets aren't met.
  • Increased competition from AI healthcare platforms could erode Tempus' market share.
  • Regulatory challenges in AI and data privacy could impact Tempus' operations.

What makes Tempus unique

  • Tempus uses AI to provide personalized treatment insights for cancer patients.
  • Their platform integrates clinical and molecular data for precision medicine.
  • Tempus' AI-driven liquid biopsy assay enhances cancer detection and profiling.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Relocation Assistance

Company Equity

Performance Bonus

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

1%
Business Wire
Feb 25th, 2025
Ares Management Upsizes Tempus Debt Facilities to $560 Million

Combined with $260 million of capital provided in 2022 and 2023, Ares Credit funds have provided Tempus a total debt package of approximately $560 million.

Pulse 2.0
Feb 24th, 2025
Tempus Secures $560M Debt Financing

Ares Management announced that Ares Credit funds provided $300 million in additional debt financing to Tempus AI, bringing the total debt package to $560 million. This financing supports Tempus' acquisition of Ambry Genetics, completed on February 3, 2025. Ares praised Tempus' growth strategy and AI-enabled solutions in medicine. Tempus' CFO, Jim Rogers, expressed appreciation for Ares' investment, which aids in enhancing healthcare technology and patient outcomes.

Hit Consultant
Feb 21st, 2025
Stemline Therapeutics To Deploy Tempus Next’S Ai-Enabled Care Pathway Intelligence Platform

Stemline Therapeutics to Deploy Tempus Next’s AI-Enabled Care Pathway Intelligence Platform. by Fred Pennic 02/21/2025 Leave a Comment. What You Should Know: – Tempus, a provider of AI-driven precision medicine, and Stemline Therapeutics, Inc. (“Stemline”), a wholly-owned subsidiary of the Menarini Group announced a new collaboration to improve the use of ESR1 testing in metastatic breast cancer (mBC). – The partnership will leverage Tempus’ Next platform, an AI-enabled care pathway intelligence tool, to help clinicians determine when ESR1 testing may be appropriate for their patients.Challenges in ESR1 TestingESR1 mutations are a critical factor in the progression of ER+/HER2- mBC, a common type of breast cancer. Up to 50% of patients with this type of cancer can develop ESR1 mutations after prior endocrine therapy. Recognizing this, the American Society of Clinical Oncology (ASCO) recommends ESR1 mutation testing at each disease progression. Tempus Next: Guiding Clinical DecisionsTempus’ Next platform will analyze clinical data from mBC patients and notify clinicians when ESR1 testing is missing at disease progression

ETF Daily News
Feb 15th, 2025
Apollon Wealth Management LLC Makes New $256,000 Investment in Tempus AI, Inc. (NASDAQ:TEM)

Apollon Wealth Management LLC makes new $256,000 Investment in Tempus AI, Inc. (NASDAQ:TEM).

Money Morning
Feb 14th, 2025
Nancy Pelosi's Favorite AI Stock Rising Again After 13% Surge

Tempus announced yesterday that it was collaborating with the nonprofit Institute for Follicular Lymphoma Innovation to develop treatment options for patients with the disease.

INACTIVE